Market Herald logo


Be the first with the news that moves the market
  • Neuroscientific Biopharmaceuticals (NSB) has released an underwhelming study for its Alzheimer’s treatment
  • The company had a breakthrough in July but has since struggled to bring in more strong results
  • Apparently, there is a lack of animals that replicate the disease as it occurs in humans
  • Neuroscientific’s share price crashed today, dropping 28.81 per cent to 21 cents per share.

Neuroscientific Biopharmaceuticals (NSB) shares have suffered a mighty blow after some underwhelming results from its latest EmtinB study.

The company saw a major breakthrough in its EmtinB treatment’s potential to treat Alzheimer’s Disease in early July, resulting in shares spiking from 14 cents each to 42 cents each in one day.

Today, however, the company announced it is struggling to pull further strong results from another mouse study.

July’s study showed the drug’s ability to repair damaged neurons, paving the way for breakthrough Alzheimer’s treatments. But the company said today there is a lack of animals that replicate the disease as it occurs in humans — which means translating the treatment from mouse or pig studies into humans can be tough.

The latest EmtinB study showed the treatment had no effect on reducing neuroinflammation — or the swelling of brain tissue — in the test subjects, which were in this case mice.

The company found the treatment “could be” effective at reducing gamma-Aminobutyric acid, known as GABA, which is a type of acid that acts as a neurotransmitter in your brain. GABA is one of the identifiers of Alzheimer’s disease.

While the study perhaps failed to yield the results Neuroscientific might have hoped for, CEO and Managing Director Matthew Liddelow said the study has still given the company some valuable information.

“While the cognitive data set appears inconclusive, we are pleased with the results on the whole as it builds our deeper understanding of this unique molecule and its correct application in the neuroscience field,” Matthew said.

Still, the market seemed disappointed with the company’s update.

Neuroscientific shares slumped 28.81 per cent today, dropping from 30 cents to 21 cents by market close. Neuroscientific’s market cap is valued at $16.46 million.

NSB by the numbers
More From The Market Herald
Heramed (ASX:HMD) - CEO and Co Founder, David Groberman

" HeraMED (ASX:HMD) raises $2.39m via convertible note placement

HeraMED (HMD) has raised roughly $2.39 million through a convertible note placement.
NeuroScientific Biopharmaceuticals (ASX:NSB) - MD and CEO, Matthew Liddelow

" NeuroScientific Biopharmaceuticals (ASX:NSB) completes safety pharmacology studies

NeuroScientific Biopharmaceuticals (NSB) has seen no adverse events during its non-clinical studies of EmtinB.
PharmAust (ASX:PAA) - Chief Scientific Officer, Dr Richard Mollard

" PharmAust (ASX:PAA) identifies optimal MPL dose for canine cancer

Clinical-stage biotech company PharmAust (PAA) has identified the optimum monepantel (MPL) drug plasma range for dogs with B-cell lymphoma.
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion Group (ASX:ALC) extends contract with Sydney Local Health District

Alcidion Group (ALC) has expanded the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD).